Healthcare -
Biotechnology - NASDAQ - US
$ 8.07
-4.45 %
$ 563 M
Market Cap
-1.53
P/E
1. INTRINSIC VALUE
Balance Sheet
Phathom Pharmaceuticals, Inc.
| Current Assets | 360 M |
| Cash & Short-Term Investments | 297 M |
| Receivables | 38.8 M |
| Other Current Assets | 24.1 M |
| Non-Current Assets | 18.2 M |
| Long-Term Investments | 0 |
| PP&E | 2.09 M |
| Other Non-Current Assets | 16.1 M |
| Current Liabilities | 85.7 M |
| Accounts Payable | 10.5 M |
| Short-Term Debt | 501 K |
| Other Current Liabilities | 74.7 M |
| Non-Current Liabilities | 546 M |
| Long-Term Debt | 0 |
| Other Non-Current Liabilities | 546 M |
EFFICIENCY
Earnings Waterfall
Phathom Pharmaceuticals, Inc.
| Revenue | 55.3 M |
| Cost Of Revenue | 7.97 M |
| Gross Profit | 47.3 M |
| Operating Expenses | 325 M |
| Operating Income | -277 M |
| Other Expenses | 56.9 M |
| Net Income | -334 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Phathom Pharmaceuticals, Inc.
| Net Income | -334 M |
| Depreciation & Amortization | 795 K |
| Capital Expenditures | 0 |
| Stock-Based Compensation | 24 M |
| Change in Working Capital | 0 |
| Others | 42.7 M |
| Free Cash Flow | -267 M |
Wall Street Analysts Price Targets
Phathom Pharmaceuticals, Inc.
Wall Street analysts predict an average 1-year price target for PHAT of $19.7 , with forecasts ranging from
a
low of
$12 to a high of $28 .
PHAT Lowest Price Target
Wall Street Target
12 USD
48.70%
PHAT Average Price Target
Wall Street Target
19.7 USD
144.29%
PHAT Highest Price Target
Wall Street Target
28 USD
246.96%
4. DIVIDEND
ANALYSIS
PHAT does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
Phathom Pharmaceuticals, Inc.
Sold
0-3 MONTHS
14.2 K USD 1
3-6 MONTHS
16.7 K USD 1
6-9 MONTHS
240 K USD 3
9-12 MONTHS
0 USD 0
Bought
217 K USD 2
0-3 MONTHS
44.2 K USD 1
3-6 MONTHS
180 K USD 2
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Phathom Pharmaceuticals: Potential Blockbuster Gastric Acid-Reducing Drug With New Mechanism
VOQUEZNA's FDA exclusivity through 2032 and superior efficacy in GERD and H. pylori create a strong competitive moat in a $3.2B+ market. Rapid commercial uptake, robust DTC marketing, and >80% insurance coverage have driven $55M+ first-year sales and 390,000+ prescriptions. Discounted cash flow analysis supports a $14/share price target (43% upside potential), with near-term catalysts in sales growth, EU partnerships, and pipeline expansion.
seekingalpha.com
- 1 month ago
Phathom Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
FLORHAM PARK, N.J., June 23, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today announced that, in connection with the appointment of Anne Marie Cook as Chief Legal Officer and Corporate Secretary, the Company's Board of Directors has approved the grant of inducement awards.
globenewswire.com
- 1 month ago
Phathom Pharmaceuticals Appoints Anne Marie Cook as Chief Legal Officer and Corporate Secretary
FLORHAM PARK, N.J., June 23, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today announced the appointment of Anne Marie Cook, J.D.
globenewswire.com
- 1 month ago
Phathom Pharmaceuticals Announces FDA Correction to Orange Book Listing, Confirming 10 Years of Regulatory Exclusivity for VOQUEZNA® (vonoprazan) Tablets Through May 3, 2032
FLORHAM PARK, N.J., June 16, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today announced that the U.S. Food and Drug Administration (FDA) has updated the Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”) to accurately reflect the full 10-year period of non-patent New Chemical Entity (NCE) exclusivity for VOQUEZNA® (vonoprazan) 10 mg and 20 mg tablets.
globenewswire.com
- 1 month ago
Tiny Phathom Pharmaceuticals Just An Got FDA Blessing And Big-Time Upside: Buy
I'm bullish on Phathom Pharmaceuticals, Inc. after the FDA granted 10-year exclusivity to their flagship GI drug, Voquezna, giving them near-monopoly status. For those who don't know, this is a big deal because the FDA doesn't grant exclusivity rights often. Voquezna's prescription growth is surging, now with 390,000 fills and 127,000 in Q1 2025 alone, which is driving strong revenue momentum.
seekingalpha.com
- 1 month ago
Wall Street Analysts Believe Phathom Pharmaceuticals (PHAT) Could Rally 107.4%: Here's is How to Trade
The consensus price target hints at a 107.4% upside potential for Phathom Pharmaceuticals (PHAT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
zacks.com
- 1 month ago
Phathom Pharmaceuticals Announces Positive FDA Decision to Recognize 10 Years of Regulatory Exclusivity for VOQUEZNA® (vonoprazan) Tablets through May 3, 2032
FLORHAM PARK, N.J., June 06, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT) today announced that the U.S. Food and Drug Administration (FDA) has approved Phathom's Citizen Petition filed on December 11, 2024 and communicated the Agency's intention to correct the Orange Book to recognize the proper 10 years of New Chemical Entity exclusivity for VOQUEZNA® (vonoprazan) tablets, extending through May 3, 2032.
globenewswire.com
- 1 month ago
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
FLORHAM PARK, N.J., May 15, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, announced today that the company is scheduled to participate in the following investor conferences in May and June: H.C.
globenewswire.com
- 2 months ago
After Plunging -45.82% in 4 Weeks, Here's Why the Trend Might Reverse for Phathom Pharmaceuticals (PHAT)
Phathom Pharmaceuticals (PHAT) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
zacks.com
- 2 months ago
Phathom Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
FLORHAM PARK, N.J., May 01, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today announced that, in connection with the appointment of Jonathan Bentley as Senior Vice President, Head of Sales, the Company's Board of Directors has approved the grant of inducement awards.
globenewswire.com
- 2 months ago
Phathom Pharmaceuticals, Inc. (PHAT) Q1 2025 Earnings Call Transcript
Phathom Pharmaceuticals, Inc. (PHAT) Q1 2025 Earnings Call Transcript
seekingalpha.com
- 2 months ago
8. Profile
Summary
Phathom Pharmaceuticals, Inc. PHAT
COUNTRY
US
INDUSTRY
Biotechnology
MARKET CAP
$ 563 M
Dividend Yield
0.00%
Description
Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. Phathom Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Florham Park, New Jersey.
Contact
100 Campus Drive, Florham Park, NJ, 07932
https://www.phathompharma.com
IPO
Date
Oct. 25, 2019
Employees
427
Officers
Mr. Martin J. Gilligan
Chief Commercial Officer
Mr. David A. Socks
Co-Founder & Director
Dr. Azmi Nabulsi M.D., M.P.H.
Co-Founder & Chief Operating Officer
Mr. Tom Harris
Chief Development Sciences Officer
Ms. Molly Henderson CPA, MBA
Chief Financial & Business Officer
Mr. Steven L. Basta M.B.A.
Chief Executive Officer, President & Director
Mr. Jonathan Bentley
Senior Vice President & Head of Sales
Mr. Paul Cocja
Chief People Officer
Dr. Eckhard Leifke M.D., Ph.D.
Chief Medical Officer